Abstract
Currently, there is insufficient data in the literature on the effect of the rate of regression of sub- and intraretinal fluid on the dynamics of maximum corrected visual acuity in the treatment of neovascular age-related macular degeneration (nAMD) against the background of the use of brolucizumab. In the course of the study, it was found that rapid resorption of intraretinal and subretinal fluid does not affect the functional results of treatment, and the severity of retinal edema at the start of therapy affects the timing of reducing the thickness of the central retinal zone. Keywords: neovascular age-related macular degeneration, brolucizumab, the rate and completeness of fluid regression
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
